MCM
PACB icon

Manchester Capital Management’s Pacific Biosciences PACB Stock Holding History

Manchester Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-464
Closed -$5.37K – 1100
2023
Q1 		$5.37K Sell
464
-42
-8% -$418 ﹤0.01% 611
2022
Q4 		$4.14K Sell
506
-228
-31% -$1.96K ﹤0.01% 560
2022
Q3 		$4K Sell
734
-5,073
-87% -$29.1K ﹤0.01% 549
2022
Q2 		$26K Buy
5,807
+299
+5% +$1.82K ﹤0.01% 395
2022
Q1 		$50K Buy
5,508
+147
+3% +$1.69K 0.01% 400
2021
Q4 		$110K Buy
5,361
+5,021
+1,477% +$121K 0.01% 330
2021
Q3 		$9K Buy
+340
New +$10.1K ﹤0.01% 603

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Manchester Capital Management's PACB Position: Q2 2023 in Review

Manchester Capital Management sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 464 shares — an estimated $5.37K sold.

Manchester Capital Management first reported a position in PACB in Q3 2021 and held it in 7 quarters. The position peaked at $110K in Q4 2021. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Manchester Capital Management reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Manchester Capital Management sold 464 Pacific Biosciences shares in Q2 2023, an estimated $5.37K.
  • Manchester Capital Management first reported a position in Pacific Biosciences in Q3 2021 and held it in 7 quarters.
  • Manchester Capital Management's Pacific Biosciences position peaked at $110K in Q4 2021.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Manchester Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.